This new strategy to reduce the risk of stroke in patients with atrial fibrillation is technically feasible and safe, even though long-term outcomes are yet to be seen and despite the evidence available, for instance, left atrial appendage closure devices. It is true that they could be used simultaneously, but its synergy and cost have<a href="https://solaci.org/en/2019/08/29/permanent-carotid-coil-filters-in-patients-with-atrial-fibrillation/" title="Read more" >...</a>
This device, an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent manufactured in China, showed very similar efficacy and safety to the “gold standard” everolimus eluting Xience at 2-year follow up, according to the TARGET outcomes, presented yesterday at the EuroPCR 2019 and simultaneously published in J Am Coll Cardiol Intv. The device, which is manufactured in China<a href="https://solaci.org/en/2019/05/27/europcr-2019-stent-firehawk-continues-to-show-good-results-at-2-years-vs-xience/" title="Read more" >...</a>
Data from randomized studies are also supported by the SCAAR registry, in which ultrathin-strut stents show real-world advantages. Patients with small vessels who received ultrathin-strut stents are less likely to undergo revascularization at 3 years than those who received first-generation thin-strut devices, according to the BIO-RESORT trial, presented during the first day of the annual<a href="https://solaci.org/en/2019/05/23/europcr-2019-bio-resort-and-scaar-registry-ultrathin-struts-also-in-small-vessels-pequenos/" title="Read more" >...</a>
In the 2018 Guidelines on Hypertension, commandment no. 6 states that we should make lifestyle interventions such as sodium restriction, healthy eating, regular exercise, weight control, and smoking cessation, and also alcohol moderation. It is clear that heavy alcohol consumption induces hypertension and may probably be one of the main causes of secondary hypertension, but<a href="https://solaci.org/en/2019/05/13/is-alcohol-good-bad-or-neutral-for-cardiovascular-health/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR) is more common than we thought. Around 1.6 million people in the US and over 3 million in Europe experience significant TR. It usually has a functional cause and its negative impact on patient prognosis is strong. Its surgical treatment is challenging, and it is important that its resolution<a href="https://solaci.org/en/2019/05/03/promising-results-for-tricuspid-repair/" title="Read more" >...</a>
This large cohort of patients treated with the dual therapy COMBO stent has showed excellent outcomes after one year (MASCOT Post Marketing Registry). Long term follow up is still ongoing. The COMBO stent is a new device with an abluminal sirolimus biodegradable polymer and a luminal layer of antibodies that promotes endothelial healing (anti CD34+)<a href="https://solaci.org/en/2019/03/11/abluminal-sirolimus-and-luminal-cd34-antibody-layer-is-combo-the-future-of-stents/" title="Read more" >...</a>
Pulmonary artery denervation is associated with significant hemodynamics improvement, as well as improved clinical outcomes in patients with both post and precapillary pulmonary hypertension. Even though there are several studies on this technique, they included few patients (with different criteria and different devices), which is why we need more randomized studies. This prospective, randomized, study<a href="https://solaci.org/en/2019/03/07/pulmonary-artery-denervation-starts-to-show-results/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Mitral regurgitation is the most frequent type of valve disease, accounting for >6% of patients over 65 years old. Surgery is currently the strategy of choice, but percutaneous treatment is a valid alternative. The long-term progress of symptomatic patients at high surgical risk who do not meet the formal indications for<a href="https://solaci.org/en/2019/02/01/good-outcomes-for-mitraclip-off-label/" title="Read more" >...</a>
The Fourth Universal Definition of Myocardial Infarction is a document developed jointly by the European Society of Cardiology (ESC), the American College of Cardiology (ACC), the American Heart Association (AHA), and the World Heart Federation (WHF). The Fourth Definition was necessary for multiple reasons, including increasingly higher troponin sensitivity. While troponin obviously does not<a href="https://solaci.org/en/2019/01/30/the-ten-commandments-for-the-fourth-universal-definition-of-infarction/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Aortic stenosis happens in 2.8% of patients over 75, and is even more frequent in dialysis patients. However, it remains unclear whether kidney dysfunction increases the risk of aortic stenosis. The present study looked at 1,121,875 patients from the SCREAM project (Stockholm CREAtinine Measurements). Mean age was 50, and<a href="https://solaci.org/en/2019/01/29/are-aortic-stenosis-and-kidney-dysfunction-associated/" title="Read more" >...</a>